摘要
英夫利昔单抗(Infliximab,IFX),作为一种肿瘤坏死因子-α拮抗剂(Tumor necrosis factor-αantagonist,TNF-αAntagonist),是中-重度溃疡性结肠炎(Ulcerative colitis,UC)的一线用药。目前,英夫利昔单抗(Infliximab,IFX)为国内外应用最广的生物制剂。溃疡性结肠炎是一种可全结肠受累的自身免疫性肠道炎性疾病,是炎症性肠病(Inflammatory bowel disease,IBD)的一种亚型;英夫利昔单抗的疗效在溃疡性结肠炎中得到广泛认可,但用药期间的不良反应发生率正大幅提高,尤其是皮肤系统的不良反应事件,本文报道了1例在应用英夫利昔单抗后出现掌跖脓疱病的病例,经专科干预后病情有所好转,病变持续了半年之久,在整个病程中未停止英夫利昔单抗的治疗,分析其中原因,可能与应用类克的累积剂量相关。提示我们在使用英夫利昔单抗的同时注意药物安全性,及时采取必要的措施,尽量避免不良反应,以免导致病情加重。
Infliximab(IFX),as a tumor necrosis factor-αantagonist(TNF-αantagonist),is the first-line medicine in the treatment of moderate-severe ulcerative colitis(UC).At present,IFX is a biological agent most widely used in the world.UC is an autoimmune intestinal inflammatory disease that can involve the whole colon.It is a subtype of inflammatory bowel disease(IBD).The efficacy of IFX has been widely recognized in UC,but the incidence of adverse reactions during the treatment is greatly increasing,especially in the skin system.We reported a case of palmoplantar pustules(PPP)after IFX therapy for UC,which was improved after dermatological intervention.The lesions lasted for half a year.The treatment of IFX continued in the entire course.The reason may be related to the cumulative dose of IFX.It is suggested that we should pay more attention to the safety of IFX and take necessary measures to avoid adverse reactions and avoid aggravation of the disease.
作者
杨美琪
刘维新
兰雨桐
邓秋萍
梁增
李雪梅
YANG Mei-qi;LIU Wei-xin;LAN Yu-tong;DENG Qiu-ping;LIANG Zeng;LI Xue-mei(The First Affiliated Hospital of China Medical University,Shenyang 110001,China)
出处
《实用药物与临床》
CAS
2020年第9期851-853,共3页
Practical Pharmacy and Clinical Remedies
关键词
溃疡性结肠炎
英夫利昔单抗
掌跖脓疱病
炎症性肠病
Ulcerative colitis(UC)
Infliximab(IFX)
Palmoplantar pustulosis(PPP)
Inflammatory bowel disease(IBD)
